Harrow- 8.625% NT REDEEM 30/04/2026 USD 25 Receivables

Harrow- 8.625% NT REDEEM 30/04/2026 USD 25 posts a receivables of $100M as of March 2026. That compares with $77M in the prior-year period — up 31.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's receivables was $77M. The latest reading is $100M — a 31.0% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's financial statement story. At $100M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for HROWL's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's other metric pages and overview cover the third.

Judging Harrow- 8.625% NT REDEEM 30/04/2026 USD 25 against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $100M here, then scan peer and history charts to see if the gap is persistent.